244 related articles for article (PubMed ID: 15844767)
1. [Prognostic value of serum beta2-microglobulin in multiple myeloma].
Bettini R; Redaelli S; Maino C; Bertuol S; Costantini C; Lazzarini A; Brivio L; Gorini M
Recenti Prog Med; 2005 Feb; 96(2):81-6. PubMed ID: 15844767
[TBL] [Abstract][Full Text] [Related]
2. [Prognostic analysis and assessment on the clinical staging systems of multiple myeloma--a report of 206 cases].
Tao ZF; Fu WJ; Chen YB; Yuan ZG; Wang DX; Hou J
Ai Zheng; 2006 Apr; 25(4):461-4. PubMed ID: 16613681
[TBL] [Abstract][Full Text] [Related]
3. Prognostic factors and staging systems of multiple myeloma:
Tao ZF; Fu WJ; Yuan ZG; Wang DX; Chen YB; Hou J
Chin Med J (Engl); 2007 Oct; 120(19):1655-8. PubMed ID: 17935664
[TBL] [Abstract][Full Text] [Related]
4. Stratification of multiple myeloma according to serum beta 2-microglobulin and serum albumin levels.
Scudla V; Budíková M; Fischerová E; Zadrazil J; Indrák K
Acta Univ Palacki Olomuc Fac Med; 1991; 130():201-12. PubMed ID: 1838869
[TBL] [Abstract][Full Text] [Related]
5. Plasma cell growth fraction using Ki-67 antigen expression identifies a subgroup of multiple myeloma patients displaying short survival within the ISS stage I.
Gastinne T; Leleu X; Duhamel A; Moreau AS; Franck G; Andrieux J; Lai JL; Coiteux V; Yakoub-Agha I; Bauters F; Harousseau JL; Zandecki M; Facon T;
Eur J Haematol; 2007 Oct; 79(4):297-304. PubMed ID: 17692103
[TBL] [Abstract][Full Text] [Related]
6. International prognostic index (IPI)--a critical comparison with five multiple myeloma staging systems in the group of 270 patients treated by conventional chemotherapy.
Scudla V; Zemanova M; Minarik J; Bacovsky J; Ordeltova M; Indrak K; Budikova M; Dusek L; Farbiakova V
Neoplasma; 2006; 53(4):277-84. PubMed ID: 16830053
[TBL] [Abstract][Full Text] [Related]
7. [Prognostic effect of beta 2-microglobulin in multiple myeloma].
Ortega F; González M; Moro MJ; Gascón A; Duarte I; Martín M; Hernández J; Jiménez-Galindo R; Portero JA; Sanz M
Med Clin (Barc); 1992 Nov; 99(17):645-8. PubMed ID: 1447935
[TBL] [Abstract][Full Text] [Related]
8. International staging system for multiple myeloma.
Greipp PR; San Miguel J; Durie BG; Crowley JJ; Barlogie B; Bladé J; Boccadoro M; Child JA; Avet-Loiseau H; Kyle RA; Lahuerta JJ; Ludwig H; Morgan G; Powles R; Shimizu K; Shustik C; Sonneveld P; Tosi P; Turesson I; Westin J
J Clin Oncol; 2005 May; 23(15):3412-20. PubMed ID: 15809451
[TBL] [Abstract][Full Text] [Related]
9. Time to first disease progression, but not beta2-microglobulin, predicts outcome in myeloma patients who receive thalidomide as salvage therapy.
Palumbo A; Bringhen S; Falco P; Cavallo F; Ambrosini MT; Avonto I; Gay F; Caravita T; Bruno B; Boccadoro M
Cancer; 2007 Aug; 110(4):824-9. PubMed ID: 17594696
[TBL] [Abstract][Full Text] [Related]
10. Simple prognostic model for patients with multiple myeloma: a single-center study in Japan.
Kaneko M; Kanda Y; Oshima K; Nannya Y; Suguro M; Yamamoto R; Chizuka A; Hamaki T; Matsuyama T; Takezako N; Miwa A; Togawa A
Ann Hematol; 2002 Jan; 81(1):33-6. PubMed ID: 11807633
[TBL] [Abstract][Full Text] [Related]
11. Total soluble HLA class I and soluble HLA-G in multiple myeloma and monoclonal gammopathy of undetermined significance.
Leleu X; Le Friec G; Facon T; Amiot L; Fauchet R; Hennache B; Coiteux V; Yakoub-Agha I; Dubucquoi S; Avet-Loiseau H; Mathiot C; Bataille R; Mary JY;
Clin Cancer Res; 2005 Oct; 11(20):7297-303. PubMed ID: 16243800
[TBL] [Abstract][Full Text] [Related]
12. Beta2-microglobulin is a better predictor of treatment-free survival in patients with chronic lymphocytic leukaemia if adjusted according to glomerular filtration rate.
Delgado J; Pratt G; Phillips N; Briones J; Fegan C; Nomdedeu J; Pepper C; Aventin A; Ayats R; Brunet S; Martino R; Valcarcel D; Milligan D; Sierra J
Br J Haematol; 2009 Jun; 145(6):801-5. PubMed ID: 19388937
[TBL] [Abstract][Full Text] [Related]
13. Staging multiple myeloma patients with active disease using serum levels of beta2m-free HLA class I heavy chain together with IgM or platelet count.
Perosa F; Minoia C; Favoino E; Prete M; Dammacco F
Blood Cells Mol Dis; 2009; 42(1):71-6. PubMed ID: 18996035
[TBL] [Abstract][Full Text] [Related]
14. [Clinical usefulness of serum beta2-microglobulin determination in patients with multiple myeloma].
Kraj M; Maj S; Pogłód R; Rostkowska J
Acta Haematol Pol; 1989; 20(2):140-51. PubMed ID: 2700533
[TBL] [Abstract][Full Text] [Related]
15. [Analysis of the international staging system of multiple myeloma and its comparison with the DS and IFM staging system in 122 Chinese patients].
Deng SH; Xu Y; Mai YJ; Wang YF; Zhao YZ; Zou DH; Qiu LG
Zhonghua Xue Ye Xue Za Zhi; 2008 Apr; 29(4):217-21. PubMed ID: 18843972
[TBL] [Abstract][Full Text] [Related]
16. [The prognostic significance of the beta 2-microglobulin level of the blood serum in multiple myeloma patients].
Lubo-Lesnichenko IF; Bessmel'tsev SS; Abdulkadyrov KM; Blinov MN; Stel'mashenko LV
Ter Arkh; 1996; 68(10):28-31. PubMed ID: 9026938
[TBL] [Abstract][Full Text] [Related]
17. Erythropoiesis-stimulating agents are associated with reduced survival in patients with multiple myeloma.
Katodritou E; Verrou E; Hadjiaggelidou C; Gastari V; Laschos K; Kontovinis L; Kapetanos D; Constantinou N; Terpos E; Zervas K
Am J Hematol; 2008 Sep; 83(9):697-701. PubMed ID: 18626886
[TBL] [Abstract][Full Text] [Related]
18. Beta-2-microglobulin level predicts outcome following autologous hematopoietic stem cell transplantation in patients with multiple myeloma.
Stella-Holowiecka B; Czerw T; Holowiecka-Goral A; Giebel S; Wojnar J; Holowiecki J
Transplant Proc; 2007 Nov; 39(9):2893-7. PubMed ID: 18022010
[TBL] [Abstract][Full Text] [Related]
19. [Prognostic value of the new international staging system in multiple myeloma. Comparison with Durie-Salmon staging system].
Conté L G; Figueroa M G; Lois V V; Cabrera C ME; León R A; García L H; Rojas R H
Rev Med Chil; 2008 Jan; 136(1):7-12. PubMed ID: 18483648
[TBL] [Abstract][Full Text] [Related]
20. [Prognostic factors and markers of activity in multiple myeloma (results of the Cooperative Group for Diagnosis and Treatment of Multiple Myeloma)].
Spicka I; Cieslar P; Procházka B; Jirsa M; Chrz M; Gregora E; Klener P
Cas Lek Cesk; 2000 Apr; 139(7):208-12. PubMed ID: 10916207
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
